The job is part of a £400m investment package at Fujifilm’s Diosynth Biotechnologies’ UK site to expand cell culture capabilities, viral vector and gene therapy services and microbial production.

At the time of the announcement in December 2021, the then prime minister Boris Johnson said: “At £400m, this is a significant investment in British biopharmaceutical manufacturing and will power our response to some of today’s most urgent global health challenges and deliver life-changing medicines and vaccines to patients in need.”

K Rouse are undertaking drainage, earthworks and foundation works on this scheme.